Show simple item record

dc.contributor.authorReichardt, P
dc.contributor.authorLeahy, Michael G
dc.contributor.authorGarcia Del Muro, X
dc.contributor.authorFerrari, S
dc.contributor.authorMartin, J
dc.contributor.authorGelderblom, H
dc.contributor.authorWang, J
dc.contributor.authorKrishna, A
dc.contributor.authorEriksson, J
dc.contributor.authorStaddon, A
dc.contributor.authorBlay, J
dc.date.accessioned2014-04-10T11:15:21Z
dc.date.available2014-04-10T11:15:21Z
dc.date.issued2012
dc.identifier.citationQuality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe (SABINE) Study. 2012, 2012:740279 Sarcomaen
dc.identifier.issn1369-1643
dc.identifier.pmid22550425
dc.identifier.doi10.1155/2012/740279
dc.identifier.urihttp://hdl.handle.net/10541/315625
dc.description.abstractThe aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120 mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease.
dc.language.isoenen
dc.rightsArchived with thanks to Sarcomaen
dc.titleQuality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe.en
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology, Oncology and Palliative Care, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, 15526 Bad Saarow, Germanyen
dc.identifier.journalSarcomaen
html.description.abstractThe aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120 mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease.


This item appears in the following Collection(s)

Show simple item record